Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus azacitidine versus azacitidine maintenance after allogeneic stem cell transplantation in high-risk MDS, CMML, and AML
ChiCTR2200058557Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of venetoclax and azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Cytogenetic and/or molecular relapse rate. Started Apr 2022; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200058557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058557.